FDA Rejects Experimental Melanoma Drug Twice Over Study Design
The Food and Drug Administration turned down an experimental melanoma treatment on two separate occasions after raising questions about how the supporting clinical study was structured. The agency cited concerns with the trial's design as the basis for both rejections.
foxbusiness.comThe Food and Drug Administration rejected an experimental melanoma drug on two occasions because it questioned the design of the clinical study submitted by the developer. Agency reviewers determined that the trial structure did not meet standards required to support approval. The same concerns were cited in both rejection decisions.
No additional details on the drug's developer, specific trial endpoints, or next steps were provided in the report.
Key Facts
Potential Impact
- 01
The developer may need to redesign the clinical study before resubmitting the application.
Transparency Panel
Related Stories
The GuardianWHO Chief Visits DRC as Ebola Death Rate Reaches 30-50%
World Health Organization director-general Tedros Adhanom Ghebreyesus arrived in the Democratic Republic of the Congo to support containment of a new Ebola outbreak. The agency revised the death rate to 30-50% based on confirmed cases and recorded 10 confirmed and 223 suspected d…
westernjournal.comGreek National Charged in UK With Aiding Iran-Linked Intelligence Service
A 46-year-old Greek man living in Germany was charged under the UK National Security Act with assisting an intelligence service believed to be Iran by targeting a journalist at Iran International.
physicianonfire.comBilt Rewards reports $1 billion revenue target for 2026
Bilt Rewards CEO Ankur Jain said the company's flagship credit card accounts for less than 11 percent of revenue. The firm now processes more than $100 billion in annual housing spend across one in four U.S. apartment buildings.